 IRVINE, Calif., June 18, 2021 GLOBE NEWSWIRE -- Tarsus Pharmaceuticals, Inc. NASDAQ: TARS, a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced it will hold a webcast and conference call on Monday, June 21, 2021 at 8:00 a.m. ET to provide a detailed summary of results from the Saturn-1 Phase 2b3 pivotal trial for TP-03 lotilaner ophthalmic solution, 0.25 for the treatment of Demodex blepharitis and a brief corporate update. 